Magnesium aspartate (magnesium 7.5mmol) effervescent tablets sugar free
Requires a prescription from a doctor or prescriber
Magnesium aspartate is a magnesium salt of aspartic acid that is commonly used as a mineral supplement.
Official documents, adverse reaction reporting, and safety monitoring
Report a side effect
Submit a Yellow Card report to the MHRA
Official medicine documents
Safety monitoring data
Yellow Card reports
The MHRA Yellow Card scheme collects reports of suspected side effects from healthcare professionals and patients. View the Drug Analysis Profile (iDAP) for real-world adverse reaction data.
View Drug Analysis Profile
Browse all Drug Analysis Profiles A–Z
Browse all iDAP reports
Interactive Drug Analysis Profiles for all medicines
Report a side effect
Submit a Yellow Card report to the MHRA
Data from the MHRA Yellow Card scheme. A reported reaction does not necessarily mean the medicine caused it. Contains public sector information licensed under the Open Government Licence v3.0.
EudraVigilance
The European Medicines Agency (EMA) collects suspected adverse reaction reports from across the EU/EEA through the EudraVigilance system. Search for safety data on this medicine.
View EudraVigilance report
Suspected adverse reactions reported for Magnesium aspartate
About EudraVigilance
Learn about EU pharmacovigilance and safety monitoring
EudraVigilance data is published by the European Medicines Agency (EMA). A suspected adverse reaction is not necessarily caused by the medicine.
1 branded products available
Therapeutically similar medicines
Similarity is based on WHO Anatomical Therapeutic Chemical (ATC) classification and on a factual NHS dm+d therapeutic-grouping code prefix. Source data: NHS dm+d via TRUD (OGL v3.0), WHO ATC/DDD Index.
NHS prescribing volume and spending trends
Guidelines from the National Institute for Health and Care Excellence
NICE clinical guidance(3)
Preventing recurrent hypomagnesaemia: oral magnesium glycerophosphate (ESUOM4)
Hypertension in pregnancy: diagnosis and management (NG133)
Eltrombopag for treating chronic immune thrombocytopenia (TA293)
Source: National Institute for Health and Care Excellence (NICE). Contains public sector information licensed under the Open Government Licence v3.0.
Check stock at pharmacies and supply information
Pharmacy stock checkers
Search for this medicine at major UK pharmacy chains. These links open the retailer's own website — results depend on their current online catalogue.
Supply & safety information
Official UK regulator monitoring and safety alerts
Pharmacy links redirect to the retailer's own search and do not represent real-time stock levels. Shortage and safety information sourced from MHRA drug safety updates (gov.uk, Crown Copyright under OGL v3.0).
Codes for healthcare professionals and prescribing systems
These codes are used by healthcare IT systems and prescribers to identify this medicine.
NHS UK identifiers
Browse tools
SNOMED CT and dm+d codes from NHS TRUD (Technology Reference data Update Distribution), licensed under the Open Government Licence v3.0. BNF code shown is the factual mapping value distributed by NHS Business Services Authority (NHSBSA) in the dm+d supplementary file under OGL v3.0; it is not affiliated with, nor licensed from, the publishers of the British National Formulary. ATC codes from the WHO Collaborating Centre for Drug Statistics Methodology (whocc.no).
Active and completed clinical studies from ClinicalTrials.gov
Source: ClinicalTrials.gov, a database of the U.S. National Library of Medicine (NLM), National Institutes of Health (NIH). Data accessed via ClinicalTrials.gov API v2. Trial information is provided for research purposes and does not constitute medical advice.
Academic studies and reviews for this medicine's active substance
Showing the 50 most relevant studies.
Reviews & meta-analyses: 16 · Randomised trials: 7 · 1983–2026
Showing the 50 most relevant studies, sorted by most relevant.
Colin J. L. McCartney, Avinash Sinha, Joel Katz
Anesthesia & Analgesia, 2004
- Analgesics, Opioid
- Anesthetics, Dissociative
- Clinical Trials as Topic
Asokumar Buvanendran, Robert J. McCarthy, Jeffrey S. Kroin, et al.
Anesthesia & Analgesia, 2002
- Analgesics, Opioid
- Blood Pressure
- Fentanyl
Keith W. Muir, Kennedy R. Lees
Stroke, 1995
- Acute Disease
- Blood Pressure
- Cerebrovascular Disorders
L. Rodríguez-Rubio, E. Nava, Julián Solís García del Pozo, et al.
Journal of clinical anesthesia, 2017
Argeros Z, Xu X, Bhandari B, et al.
2025
- Hypertension
- Magnesium
- Blood Pressure
BackgroundThere are inconsistent reports regarding the effect of magnesium intake on blood pressure (BP) across hypertensive and normotensive populations.MethodsWe performed a meta-analysis and dose-response analysis to explore the relationship between magnesium supplementation and BP in randomized-controlled trials with a duration of ≥4 weeks, using a cubic spline regression model.ResultsThirty-eight randomized controlled trials involving 2709 participants were eligible for inclusion. Studies included an elemental magnesium dose from 82.3 mg to 637 mg with a median dose of 365 mg and a median intervention period of 12 weeks. Mean differences of changes in BP were calculated by random effects meta-analysis. Magnesium intake resulted in a reduction in systolic BP of -2.81 mm Hg (95% CI, -4.32 to -1.29) and diastolic BP by -2.05 mm Hg (95% CI, -3.23 to -0.88) compared with placebo. Hypertensive individuals on BP-lowering medication and individuals with hypomagnesemia yielded greater systolic BP reductions of -7.68 and -5.97 mm Hg, respectively (PPP≥0.20).ConclusionsOur findings support the beneficial effect of magnesium on reducing BP among populations with hypertension and hypomagnesemia, although effects should be interpreted with caution due to high heterogeneity of studies. Larger, well-designed studies assessing higher magnesium doses are needed to refine the dose-response relationship between magnesium intake and BP and identify potential optimal supplementation strategies for subpopulations.
Abstract licence: CC BY
En-Bo Wu, Kuen-Lin Wu, Wei-Ti Hsu, et al.
Pharmaceuticals, 2025
Habiblah Jagunmolu, Emmanuel Oyetola, Yusuff Lawal, et al.
The Egyptian Journal of Neurology, Psychiatry and Neurosurgery, 2026
Zhou J, Wen Y, Xu S, et al.
2026
Owayed A, Alshammari HA, Aljumaiaan M, et al.
2025
Kubbara EA, Hamdan SZ, Hajali TA, et al.
2026
- Diabetic Retinopathy
- Diabetes Mellitus, Type 2
- Magnesium
Sources: aggregated from Europe PMC (EMBL-EBI), OpenAlex, Crossref, PubMed and other open scholarly databases. Retracted articles are excluded. Study information is provided for research purposes and does not constitute medical advice.
Pharmacology and chemical data from DrugBank
Key facts
Drug status
Investigational
Major interactions
70 found
Half-life
Not available
Mechanism
Not available
Food interactions
None known
Human targets
None mapped
Data: DrugBank · CC BY-NC 4.0
Pharmacokinetics at a glance
Known interactions with other medications. Always consult a healthcare professional.
Showing 50 of 251 interactions
ATC A12CC05
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Show
Chemical identifiers
CAS, UNII, InChI Key and database cross-references
Linked compound data from DrugBank Open Data (CC BY-NC 4.0)
Magnesium aspartate
DrugBank citations
If you use DrugBank data in your research, please cite the following publications:
Show earlier publications
Structured knowledge from the free knowledge base
ATC classifications (Wikidata)
Linked open data from Wikidata (Q6731379), a free and open knowledge base operated by the Wikimedia Foundation. Data is available under the Creative Commons CC0 1.0 Public Domain Dedication.